IBA Launches QUASAR Penta-Guide QA Phantom for Radiotherapy

IBA (Ion Beam Applications S.A., EURONEXT) announced on 27 September 2026 the launch of the QUASAR Penta-Guide Performance Phantom, a radiotherapy quality assurance device that performs more than 25 imaging and machine QA tests in a single setup. The Belgian particle accelerator company said the phantom combines 2D and 3D imaging checks with integrated analysis software for image-guided and CBCT-based adaptive radiotherapy workflows. IBA employs roughly 2,300 people worldwide and is listed on EURONEXT under the ticker IBA. The company did not disclose pricing, order volumes or unit targets for the new device.

Context — Why radiotherapy QA tools matter now

The launch lands as radiotherapy departments absorb image-guided and adaptive treatment workflows, which demand more frequent and more granular verification than fixed-field techniques. IBA frames the phantom as a response to that shift: it consolidates imaging and machine QA into one device rather than spreading checks across several phantoms and separate analysis tools. The company said the goal is fewer repeated setups and less procedural variability.

The report gives no prior-period comparison for IBA Dosimetry's QA portfolio, no unit volumes and no revenue contribution from the new phantom. What it does give is a portfolio framing: the phantom expands the existing QUASAR line, which IBA positions as its radiotherapy QA franchise.

Jean-Marc Bothy, President of IBA Dosimetry, tied the design to clinical workflow, saying the phantom was developed around the realities of modern clinical practice and helps teams work more efficiently while keeping the consistency required for image-guided and adaptive radiotherapy. He added that the device supports safer treatment delivery and broader patient access to high-quality care. Those are the company's stated expectations, not verified outcomes.

Adaptive radiotherapy adjusts treatment to anatomical changes during a course of care, which raises the bar for verifying that imaging systems and beam delivery stay aligned. A phantom that checks both in one session addresses a workflow problem clinicians face daily, though IBA did not quantify the time saved.

IBA holds a B Corporation certification and operates in proton therapy, industrial sterilization, radiopharmaceuticals and dosimetry. Dosimetry is the segment housing the QUASAR portfolio, so the launch is an incremental product event inside a broader business, not a new market entry.

Data — What the numbers in the report show

The headline figure is test capacity: more than 25 imaging and machine QA tests from one setup. IBA pairs that with integrated software supporting DICOM handling, automated data analysis, report generation and performance trending.

Element	Report detail
QA tests per setup	More than 25
Imaging modes	2D and 3D
Workflow support	Image-guided and CBCT-based adaptive radiotherapy
Software functions	DICOM handling, automated analysis, reporting, trending
Employees (company-wide)	Approximately 2,300

The report provides no price, no per-unit cost, no revenue guidance and no comparison against IBA's earlier phantom models. In the absence of those figures, the test count and the software feature list are the only quantitative anchors. IBA also did not say how many clinics have ordered the device or when shipments begin.

For context on scale, the roughly 2,300-employee figure covers the whole group across proton therapy, sterilization, radiopharmaceuticals and dosimetry. The phantom sits inside the smallest of those in revenue terms, though IBA does not break out dosimetry revenue in the report.

Analysis — What it means for medtech and radiotherapy suppliers

The phantom competes in a niche where the buyer is a hospital physics department, not a consumer or an industrial purchaser. Demand tracks the installed base of linear accelerators and the pace at which clinics adopt adaptive workflows. IBA's own proton therapy business is a natural internal channel, since proton centers already run complex QA programs.

Second-order effects run through the radiotherapy supply chain rather than through IBA alone. Clinics weighing image-guided and adaptive upgrades need QA hardware that matches the imaging modality, and a single phantom covering 2D and 3D checks lowers the equipment count a department must buy and maintain. That favors vendors with integrated software, because trending and reporting features reduce physicist hours per test.

The main limitation is disclosure. IBA gave no pricing, no order book and no timeline for commercial shipments, so the revenue contribution cannot be sized from this announcement. A further caveat: consolidation claims depend on clinical validation, and the report cites no independent study confirming that one phantom matches the accuracy of the multiple devices it replaces.

Positioning-wise, this is a product-cycle story for a small-cap EURONEXT name rather than a flow event. Investors tracking IBA will weigh it against proton therapy order momentum and dosimetry attach rates, neither of which the report updates. The device expands an existing franchise; it does not open a new end market.

Outlook — What to watch next

IBA did not disclose a commercial launch date, pricing or first-shipment timing, so the near-term catalysts are the company's own disclosures. Watch for IBA's next quarterly update for any dosimetry segment commentary or order intake tied to the QUASAR line. Watch for clinical adoption signals from radiotherapy departments running image-guided and CBCT-based adaptive programs, since those are the stated target users.

On the corporate side, IBA's EURONEXT listing means any guidance revision or segment reclassification would surface through regulated filings rather than product announcements. The report gives no share price level, no moving average and no valuation metric, so there is no technical threshold to cite here.

The practical test is whether the phantom appears in hospital procurement cycles alongside adaptive radiotherapy investments. If clinics are upgrading imaging hardware, QA spend typically follows. IBA has framed the product around that linkage but has not quantified it.

Frequently Asked Questions

What does the QUASAR Penta-Guide Performance Phantom actually do?

It is a radiotherapy quality assurance device that runs more than 25 imaging and machine QA tests in a single setup, according to IBA. It supports 2D and 3D imaging checks and is designed for image-guided and CBCT-based adaptive radiotherapy workflows. Integrated software handles DICOM files, automated data analysis, report generation and performance trending, which IBA says reduces manual analysis and supports consistent documentation.

Why did IBA build one phantom instead of several QA tools?

IBA said the design targets workflow efficiency. Consolidating imaging and machine QA checks into one device reduces the number of phantoms, repeated setups and separate analysis tools a clinic needs. The company expects that to cut procedural variability and support more consistent routine testing. IBA did not publish measured time savings or accuracy comparisons against multi-device setups.

What does this launch mean for IBA shareholders?

It is a product expansion inside IBA Dosimetry's existing QUASAR portfolio, not a new business line. IBA disclosed no pricing, order volumes or revenue guidance for the phantom, so the financial contribution cannot be estimated from this announcement. Shareholders would need IBA's next segment update to gauge commercial traction. This is informational only and not investment advice.

Bottom Line

IBA added a consolidated radiotherapy QA phantom to its QUASAR line, but disclosed no pricing, orders or shipment timing.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.